Sunlenca (Lenacapavir 300 mg Tablets)

Sunlenca (Lenacapavir 300 mg Tablets) – Gilead Sciences

Description:
Sunlenca (Lenacapavir) 300 mg is an innovative long-acting HIV-1 capsid inhibitor developed by Gilead Sciences. It is indicated for the treatment of multi-drug-resistant HIV-1 infection in adults who have limited treatment options due to resistance, intolerance, or safety concerns with other antiretroviral drugs.

The 300 mg tablets are used during the loading phase of therapy before transitioning to the long-acting subcutaneous injection. Lenacapavir provides potent viral suppression by targeting multiple stages of the HIV replication cycle, offering a new mechanism of action compared to traditional ART regimens.

Dosage Form:

• Film-coated tablets, 300 mg each
• For oral use under the supervision of a healthcare professional

Mechanism of Action:
Lenacapavir binds to the HIV-1 capsid protein, disrupting key processes required for viral replication — including capsid assembly, nuclear import, and virion maturation. This results in effective inhibition of HIV replication and long-term viral suppression.

Key Benefits:

• First-in-class capsid inhibitor
• Effective against multi-drug-resistant HIV-1
• Convenient short oral phase before long-term injection therapy
• Provides high barrier to resistance

Adverse Effects:
Common side effects include mild nausea, fatigue, and headache. Serious adverse reactions are rare and should be reported to a healthcare provider.

Manufacturer:
Gilead Sciences, Inc.
USA / EU